Table 1 Comparison of clinical and pathological characteristics of three cohorts

Age

57.7 ± 12.0

0.390

56.8 ± 11.7

0.426

65.0 ± 9.0

0.789

Sex

0.780

0.478

0.283

 Male

172 (64.4%)

62 (54.4%)

20 (45.5%)

 Female

95 (35.6%)

52 (45.6%)

24 (54.5%)

Tumor location

0.939

0.063

0.063

 Left

140 (52.4%)

45 (39.5%)

26 (59.1%)

 Right

127 (47.6%)

69 (60.5%)

18 (40.9%)

Tumor maximum diameter

4.3 ± 2.1

< 0.001

4.6 ± 2.2

0.536

4.9 ± 2.0

0.002

Renal vein invasion

< 0.001

< 0.001

0.003

 Absent

256 (95.9%)

105 (92.1%)

39 (88.6%)

 Present

11 (4.1%)

9 (7.9%)

5 (11.4%)

Collecting system invasion

< 0.001

0.009

0.036

 Absent

179 (67%)

63 (55.3%)

29 (65.9%)

 Present

88 (33%)

52 (45.7%)

15 (34.1%)

Tumor size

3.9 ± 2.0

< 0.001

4.0 ± 1.9

0.002

4.7 ± 1.9

0.015

PT stage

< 0.001

< 0.001

< 0.001

 pT1a

168 (62.9%)

63 (55.3%)

17 (38.6%)

 pT1b

48 (18%)

23 (20.2%)

16 (36.4%)

 pT2

9 (3.4%)

5 (4.4%)

6 (13.6%)

 pT3a

39 (14.6%)

19 (16.7%)

5 (11.4%)

 pT3b

3 (1.1%)

4 (3.5%)

0

 pT3c

0

0

0

 pT4

0

0

0

PN stage

< 0.001

0.080

< 0.001

 pN0

256 (95.9%)

110 (96.5%)

37 (84.1%)

 pN1

11 (4.1%)

4 (3.5%)

7 (15.9%)

 pN2

0

0

0

ISUP grade

< 0.001

< 0.001

< 0.001

 I

68 (25.5%)

29 (25.4%)

9 (20.5%)

 II

165 (61.8%)

64 (56.1%)

21 (47.7%)

 III

29 (10.9%)

19 (16.7%)

12 (27.3%)

 IV

5 (1.9%)

2 (1.8%)

2 (4.5%)

Necrosis

< 0.001

< 0.001

< 0.001

 Absent

228 (85.4%)

91 (79.8%)

33 (75%)

 Present

39 (14.6%)

23 (20.2%)

11 (25%)

Leibovich risk groups

 Low risk

194 (72.7%)

75 (65.8%)

27 (61.4%)

 Intermediate risk

59 (22.1%)

33 (28.9%)

12 (27.3%)

 High risk

14 (5.2%)

6 (5.3%)

5 (11.3%)